<DOC>
	<DOCNO>NCT02531919</DOCNO>
	<brief_summary>This pilot phase I trial study safety long-term use sodium bicarbonate patient cancer . Sodium bicarbonate may neutralize tumor acidity result may inhibit spread tumor part body ( metastasis ) improve survival .</brief_summary>
	<brief_title>Extended Use Sodium Bicarbonate Patients With Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose concentration 0.5 g/kg/day sodium bicarbonate feasible well tolerate measure proportion subject first evidence adherence failure . SECONDARY OBJECTIVES : I . Determine dose concentration 0.5 g/kg/day sodium bicarbonate safe long term consumption ( 90 day ) measure blood pressure , rest pulse rate , basic metabolic panel assess metabolic alkalosis . OUTLINE : PHASE I ( RUN-IN/ADJUSTMENT ) : Patients receive sodium bicarbonate orally ( PO ) dissolve water thrice daily ( TID ) twice daily ( BID ) day 1-10 . The dose may adjust necessary . PHASE II ( LONG TERM ) : Patients continue receive sodium bicarbonate PO TID BID total 90 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Any cancer patient enrol study must write approval oncologist notation make patient 's chart study participation Subject without know cognitive impairment , central nervous system ( CNS ) metastasis , overt psychosis , major depression , delirium note oncology medical record Subject Karnofsky performance status scale 80 % great time consent Subject complete initial adjuvant therapy currently receive wait receive chemotherapy next 120 day Breast cancer subject may enrol receive hormonal blockade therapy Subject enrol clinical trial Subject valid work phone number contact study Subject must willing provide urine specimen pH measurement schedule clinical visit Subject must willing provide 3 mL blood sample metabolic panel schedule clinical visit Subject uncontrolled hypertension ( systolic pressure &gt; 140 , diastolic pressure &gt; 90 ) despite maximal antihypertensive therapy Subject healthy renal function : creatinine clearance : 88128 mL/min ; glomerular filtration rate ( GFR ) : &gt; 90 mL/min/1.7m^2 base standard care result older 2 week ; data exist , subject need consent blood draw basic metabolic panel ( measure creatinine ) verification Subject must inform investigational nature study must sign write informed consent accordance institutional federal guideline Subject pregnant breastfeeding time consent ; pregnancy test conduct urine sample day consent premenopausal woman Subject agree use medically approve contraception ( ie . condom , oral contraceptive ) premenopausal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>tumor acidity</keyword>
</DOC>